Sifting through countless of stocks in the Health Care Technology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Evolent Health, Inc. or Veradigm Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Evolent Health, Inc. and Veradigm Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Evolent Health, Inc. and Veradigm Inc.

Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides Machinify Auth Intelligence, an artificial intelligence tool to aid nurses and physicians in completing clinical review of prior authorization requests. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.

Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising practice management software, AI patient scheduling software, and electronic statements and payments, and payerpath clearinghouse; revenue cycle services and coding services; electronic health records solutions, which include eprescribe with EPCS, EHR software, veradigm EHR, and practice fusion EHR; and patient engagement platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as veradigm connect, veradigm app expo, and diagnostic ordering and resulting network; life sciences, health plans and payers, and providers; and veradigm eprescribe enterprise. In addition, the company offers risk adjustment solutions, such as health equity analytics, risk adjustment analytics, risk mitigator, comprehensive submissions, and utilization analytics; quality analytics, risk adjustment, and quality management; clinical data exchange and coding solutions, including echart courier, echart coder, and echart integration and analytics; clinical data registries for physicians and veradigm payer insights; provider engagement solutions; care gap alerting, gap closure services, and veradigm payerpath solutions. Further, it provides real world data solutions, such as NLP-enriched EHR data solutions, and clinical data registries; real world evidence and real-world evidence analytics platform; and digital health media solutions. Additionally, the company serves physician practices, hospitals, laboratory and radiology centers, urgent care facilities, health IT companies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

Latest Health Care Technology and Evolent Health, Inc., Veradigm Inc. Stock News

As of September 2, 2026, Evolent Health, Inc. had a $478.2 million market capitalization, compared to the Health Care Technology median of $218.2 million. Evolent Health, Inc.’s stock is up 6.9% in 2026, down 6.9% in the previous five trading days and down 55.98% in the past year.

Currently, Evolent Health, Inc. does not have a price-earnings ratio. Evolent Health, Inc.’s trailing 12-month revenue is $2.1 billion with a -24.1% net profit margin. Year-over-year quarterly sales growth most recently was 46.9%. Analysts expect adjusted earnings to reach $0.200 per share for the current fiscal year. Evolent Health, Inc. does not currently pay a dividend.

As of September 2, 2026, Veradigm Inc. had a $512.3 million market cap, putting it in the 37th percentile of all stocks. Veradigm Inc.’s stock is up 1.7% in 2026, up 1.5% in the previous five trading days and NA 0% in the past year.

Currently, Veradigm Inc. does not have a price-earnings ratio. Veradigm Inc.’s trailing 12-month revenue is $594.4 million with a -49.0% net profit margin. Year-over-year quarterly sales growth most recently was 5.0%. There are no analysts providing consensus earnings estimates for the current fiscal year. Veradigm Inc. does not currently pay a dividend.

How We Compare Evolent Health, Inc. and Veradigm Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Evolent Health, Inc. and Veradigm Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Evolent Health, Inc. and Veradigm Inc. Stock Value Grades

Company	Ticker	Value
Evolent Health, Inc.	EVH	A
Veradigm Inc.	MDRX	A

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Evolent Health, Inc. has a Value Score of 81, which is Deep Value. Veradigm Inc. has a Value Score of 99, which is Deep Value.

The Value Stock Winner: It’s a Tie!

Looking at the Value Grade breakdown above, both Evolent Health, Inc. and Veradigm Inc. have a Value Grade of A. For investors who focus solely on a company’s valuation, you will need to conduct further research into both of these companies’ other metrics to see if they could be good additions to your portfolio. It’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Evolent Health, Inc. and Veradigm Inc.’s Momentum Grades

Company	Ticker	Momentum
Evolent Health, Inc.	EVH	F
Veradigm Inc.	MDRX	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Evolent Health, Inc. has a Momentum Score of 18, which is Very Weak. Veradigm Inc. has a Momentum Score of 36, which is Weak.

The Momentum Stock Winner: No Clear Winner

Neither Evolent Health, Inc. or Veradigm Inc. has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Evolent Health, Inc. or Veradigm Inc. is the better investment when it comes to momentum.

Evolent Health, Inc. and Veradigm Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Evolent Health, Inc.	EVH	C
Veradigm Inc.	MDRX	na

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Evolent Health, Inc. has a Earnings Estimate Score of 59, which is Neutral. Veradigm Inc. does not have a meaningful Earnings Estimate Score.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Evolent Health, Inc. or Veradigm Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Evolent Health, Inc. or Veradigm Inc. is the better investment when it comes to estimate revisions.

Other Evolent Health, Inc. and Veradigm Inc. Grades

In addition to Estimate Revisions, Momentum and Value, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Evolent Health, Inc. and Veradigm Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Evolent Health, Inc. or Veradigm Inc. Stock?

Overall, Evolent Health, Inc. stock has a Value Score of 81, Momentum Score of 18 and Estimate Revisions Score of 59.

Veradigm Inc. stock has a Value Score of 99, Momentum Score of 36 and Estimate Revisions Score of .

Comparing Evolent Health, Inc. and Veradigm Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.